Trials / Terminated
TerminatedNCT03868839
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
An Open-label Feasibility Trial of Adjunctive Telmisartan in Patients With Treatment Resistant Schizophrenia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Xiaoduo Fan · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication. The Investigators hypothesize that 4 weeks of telmisartan at 80mg daily will alter blood biomarkers for inflammation and oxidative stress after 4 weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telmisartan Pill | telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks. |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2020-10-07
- Completion
- 2020-10-07
- First posted
- 2019-03-11
- Last updated
- 2022-03-02
- Results posted
- 2022-03-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03868839. Inclusion in this directory is not an endorsement.